Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 32, Number 6—June 2026

CME ACTIVITY - Synopsis

Cerebrospinal Fluid Findings among Patients with Anaplasmosis and Central Nervous Involvement, Minnesota and Wisconsin, USA

Igor DumicComments to Author , Charles W. Nordstrom, Marie Schulz, Sagar B. Dugani, John Fox, Ronin Joshua Cosiquien, Tatjana Gavrancic, Margaret Paulson, Cristian Madrid, and Wendelyn Bosch
Author affiliation: Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA (I. Dumic, C.W. Nordstrom, T. Gavrancic, M. Paulson, C. Madrid, W. Bosch); Mayo Clinic Health System, Eau Claire, Wisconsin, USA (I. Dumic, C.W. Nordstrom, M. Paulson, C. Madrid); Medical College of Wisconsin–Central Wisconsin, Wausau, Wisconsin, USA (M. Schulz, J. Fox); Mayo Clinic, Rochester (S.B. Dugani); University of Minnesota Twin Cities, Minneapolis, Minnesota, USA (R.J. Cosiquien); Mayo Clinic, Jacksonville, Florida, USA (T. Gavrancic, W. Bosch)

Main Article

Table 1

Characteristics and cerebrospinal fluid findings among patients with anaplasmosis and central nervous system involvement, Minnesota and Wisconsin, USA*

Patient no. Age, y/sex Immune
status
Neurologic manifestation Sepsis ICU admission Cerebrospinal fluid results
Color Leukocyte count† Leukocyte type (%) Protein, mg/dL‡ Glucose, mg/dL§
1
75/M
IC
Left hemiparesis, meningitis
N
N
Clear
5
Lymphocyte (40)
48
56
2
65/F
IC
Meningitis
Y
Y
Clear
1
Lymphocyte (78)
33
81
3
74/F
IC
Meningitis, akathisia
N
N
Clear
1
Lymphocyte (83)
33
67
4
57/M
IS
Meningitis
N
N
Clear
0
NA
31
61
5
57/M
IS
Meningitis
Y
Y
Clear
50
Lymphocyte (78)
40
58
6
67/F
IC
Meningitis
N
N
Clear
1
Lymphocyte (72)
34
66
7
60/M
IC
Meningoencephalitis
N
N
Clear
15
Lymphocyte (43); neutrophils (30)
27
53
8
60/F
IC
Meningoencephalitis
Y
Y
Bloody
198
Neutrophils (71)
18
60
9
70/F
IC
Meningoencephalitis
N
N
Clear
1
Lymphocyte (72)
33
80
10 70/M IC Encephalitis Y Y Clear 10 Lymphocyte (50) 189 43

*IC, immunocompetent; ICU, intensive care unit; IS, immunosuppressed; NA, not applicable. †Reference range 0. ‡Reference range <50 mg/dL. §Reference range 36–101 mg/dL.

Main Article

1These first authors contributed equally to this article.

Page created: March 30, 2026
Page updated: May 29, 2026
Page reviewed: May 29, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external